La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.

Medical history:

STATE OF ALASKA
Victim Sexual Assault Evidence Kit Medical History – Step 1B

TO BE COMPLETED BY THE MEDICAL PROVIDER
Time assessment started: _________________ pm Time assessment ended: ________________ MEDICAL HISTORY:
If yes, list: ___________________________________________________________ If yes, list: _________________________________________________________________________ Vaccine History:
Current medications (prescriptions, contraceptives, over-the-counter, herbal or home remedies):
If yes, list __________________________________________________________________________ Is the victim currently being treated for any chronic medical or mental health conditions that may impact the exam? If yes, describe ____________________________________________________________________________________ _______________________________________________________________________________________________________________ Is the victim at risk of having withdrawal/DT’s during the exam? If yes, is there a seizure history associated with withdrawal? Does the victim have any observed disabilities? If yes, describe ____________________________________________________________________________________ _______________________________________________________________________________________________________________ Does the victim have a safe living environment to return to? Any recent medical procedures/treatments (30 days) that may affect the interpretation of any physical or forensic findings? If yes, describe __________________________________________________________________________________________________ Did the victim seek medical care prior to this examination that may affect the interpretation of any physical findings or potential forensic evidence? If yes, describe __________________________________________________________________________________________________ Where: _____________________________________________ Reason for care: _________________________________________ Page 1 of 4
Rev. Date – Aug/23/2013
STATE OF ALASKA
Victim Sexual Assault Evidence Kit Medical History – Step 1B

GYNECOLOGICAL HISTORY:
LMP: _____________________________ Was LMP normal (per victim):
If no, describe ___________________________________________________________________________________________________ G __________ P ___________ Delivery in the last 8 weeks: Does victim think she could be pregnant? If yes, how many weeks: _________________________________________ Has victim been treated for an STI in the last 6 weeks? Date: ___________________ For: _____________________________ Treated with: ________________________________ PHYSICAL ASSESSMENT:
Other: _______________________________________________ Vital Signs:
General:
Yes If yes, current pain level per victim is: ______ out of 10 (0 = none, 10 = worst possible) Location of pain: _________________________________________________________________________________________ Type of pain: ____________________________________________________________________________________________ What makes pain worse: ___________________________________________________________________________________ What makes pain better: ___________________________________________________________________________________ Additional information: ____________________________________________________________________________________ ANOGENITAL EXAM SUMMARY:
Was any discharge noted prior to or during manipulation of tissue (prior to insertion of speculum)? If yes, describe _______________________________________________________________________________________________________________ _______________________________________________________________________________________________________________ Was TBD used? If no, explain: __________________________________________ If no, explain: __________________________________________ Other: _____________________________________________________ if no, explain: ________________________________________________________________ if no, explain: __________________________________________________ Did the victim complain of pain or experience pain during the exam? If yes, describe _______________________________________________________________________________________________________________ _______________________________________________________________________________________________________________ Page 2 of 4
Rev. Date – Aug/23/2013
STATE OF ALASKA
Victim Sexual Assault Evidence Kit Medical History – Step 1B

ANATOMICAL SITE:
DESCRIBE:


LABORATORY TESTING/SPECIMENS COLLECTED:



RESULTS OBTAINED AT TIME OF EXAM:

Page 3 of 4
Rev. Date – Aug/23/2013
STATE OF ALASKA
Victim Sexual Assault Evidence Kit Medical History – Step 1B

Page 4 of 4
Rev. Date – Aug/23/2013

Source: http://dps.state.ak.us/CrimeLab/docs/SAforms/V3%20Medical%20history%20step%201B.pdf

cusys.edu

Commercialization of Biomarkers BULLETIN High-throughput genomics and proteomics technologies have led to the emergence and rapid proliferation of clinical use and commercial demand for biomarkers — BIOMARKERS: molecular indicators directly and highly predictive of a biological process or that have DEFINITIONS utility as theranostics to guide therapeutic decision making. These

Chemwatch msds 5099-14

MAPEI ULTRA/BOND P990 1 K BEIGE Chemwatch Material Safety Data Sheet CHEMWATCH 5099-14 Issue Date: Mon 22-Dec-2003 CD 2005/3 Page 1 of 11 Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME SYNONYMS PRODUCT USE SUPPLIER Company: Mapei Australia P/L Address: 12 Parkview Drive Archerfield QLD, 4108 AUS Telephone: +61 7 3276 5000 Fax: +61 7 3276 5076 Se

Copyright ©2018 Sedative Dosing Pdf